Opinion|Videos|November 8, 2024
Navigating Intensive Chemotherapy in the Community Setting
Author(s)Margaret T. Kasner, MD, Christian Fidler, MD
Panelists discuss how community settings face unique challenges in delivering intensive chemotherapy regimens for secondary AML, including limited resources and expertise, but can implement best practices and leverage potential benefits of community-based care to provide effective treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In the community setting, what are some of the unique challenges faced in delivering intensive chemotherapy regimens?
- What are best practices you/your practice have implemented to mitigate these challenges?
- Please describe some of the potential benefits of treating a patient in the community setting or in the outpatient setting with intensive induction (e.g., CPX-351).
Advertisement
Related to this article
Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.
The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
5